Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Testosterone recovery post-ADT is influenced by treatment duration, baseline testosterone levels, and patient age. Younger patients and those with higher baseline testosterone levels recover more ...

Men receiving treatment for prostate cancer often face challenges that extend well beyond the disease itself. A new study led ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

A study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that most of the benefits of androgen deprivation therapy (ADT) for prostate cancer occur within the first ...

The testosterone threshold should be less than 10 ng/dL rather than less than 50 ng/dL for gauging advanced prostate cancer prognosis in patients on ADT. Examining sustained testosterone suppression ...

PSMA-617 to androgen deprivation therapy (ADT) with androgen receptor pathway inhibitor (ARPI) bettered disease control in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1.